Evidence map›Paper›PMID 38764778›Full record

ArticleAmerican journal of preventive cardiology2024

Lipoprotein subclasses are associated with Hepatic steatosis: insights from the prospective multicenter imaging study for the evaluation of chest pain (PROMISE) clinical trial.

Julia Karady, Robert W McGarrah, Maggie Nguyen, Stephanie N Giamberardino, Nandini Meyersohn, Michael T Lu, Pedro V Staziaki, Stefan B Puchner, Daniel O Bittner, Borek Foldyna and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Julia KaradyCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Robert W McGarrahDuke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Maggie NguyenDuke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Stephanie N GiamberardinoDuke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Nandini MeyersohnCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Michael T LuCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Pedro V StaziakiCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Stefan B PuchnerCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Daniel O BittnerCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Borek FoldynaCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Thomas MayrhoferCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Margery A ConnellyLabcorp Inc., Morrisville, NC, USA.
Andre TchernofQuebec Heart and Lung Institute, School of Nutrition, Laval University, Canada; Institute of Nutrition and Functional Foods, Laval University, Canada.
Phillip J WhiteDuke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Khurram NasirDivision of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA.
Kathleen CoreyDivision of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Deepak VooraDuke Precision Medicine Program, Duke University School of Medicine, Durham, NC, USA.
Neha PagidipatiDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Geoffrey S GinsburgAll of Us Research Program, National Institutes of Health, MD Innovative Imaging, Bethesda, USA.
William E KrausDuke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Udo HoffmannCardiovascular Imaging Research Center, Harvard Medical School - Massachusetts General Hospital, MA, USA.
Pamela S DouglasDuke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Svati H ShahDuke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Maros FerencikKnight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA.

Funding

Mechanisms Connecting Dysregulated Branched-Chain Alpha-Ketoacid Metabolism to Cardiac DysfunctionR01HL160689 · DUKE UNIVERSITY · 2025 to 2025
$525k
NHLBI NIH HHS R01 HL160689
6 · The paper itself

Abstract

Objectives: To determine the relationship between lipoprotein particle size/number with hepatic steatosis (HS), given its association with traditional lipoproteins and coronary atherosclerosis. Methods: Individuals with available CT data and blood samples enrolled in the PROMISE trial were studied. HS was defined based on CT attenuation. Lipoprotein particle size/number were measured by nuclear magnetic resonance spectroscopy. Principal components analysis (PCA) was used for dimensionality reduction. The association of PCA factors and individual lipoprotein particle size/number with HS were assessed in multivariable regression models. Associations were validated in an independent cohort of 59 individuals with histopathology defined HS. Results: Individuals with HS (n=410/1,509) vs those without (n=1,099/1,509), were younger (59±8 vs 61±8 years) and less often females (47.6 % vs 55.9 %). All PCA factors were associated with HS: factor 1 (OR:1.36, 95 %CI:1.21-1.53), factor 3 (OR:1.75, 95 %CI:1.53-2.02) and factor 4 (OR:1.49; 95 %CI:1.32-1.68) were weighted heavily with small low density lipoprotein (LDL) and triglyceride-rich (TRL) particles, while factor 2 (OR:0.86, 95 %CI:0.77-0.97) and factor 5 (OR:0.74, 95 %CI:0.65-0.84) were heavily loaded with high density lipoprotein (HDL) and larger LDL particles. These observations were confirmed with the analysis of individual lipoprotein particles in PROMISE. In the validation cohort, association between HS and large TRL (OR: 8.16, 95 %CI:1.82-61.98), and mean sizes of TRL- (OR: 2.82, 95 %CI:1.14-9.29) and HDL (OR:0.35, 95 %CI:0.13-0.72) were confirmed. Conclusions: Large TRL, mean sizes of TRL-, and HDL were associated with radiographic and histopathologic HS. The use of lipoprotein particle size/number could improve cardiovascular risk assessment in HS.

Indexed as

Cardiac CTHepatic steatosisLipoproteinLipoprotein particlesLipoprotein subclasses

Identifiers

PMID38764778
PMCPMC11101949

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.